Centre for Stem Cell Research
A unit of inStem, Bengaluru, Christian Medical College Capmus, Bagayam Vellore
1st to 3rd August, 2024
PROGRAMME SCHEDULE
DAY-1: Thursday, 1st August, 2024
|
1:00 to 1:05 PM
1:05 to 1:20 PM 1:20 to 1:25 PM 1:25 to 1:30 PM |
· Prayer by Chaplain
· Welcome remarks: Director, CMC / Director, InStem / Principal, CMC · Remarks by Secretary, Department of Biotechnology, Ministry of Science and Technology, Govt. of India · Closing remarks: Head, CSCR |
|
|
Session-1: Orthobiologics in Cartilage Repair Chair: Samuel Chittaranjan |
||
|
India Time |
Title |
Speaker Name |
|
1.30 to 2:00 PM |
Cell-Based Therapeutics for Arthritic Disease |
Frank Barry University of Galway, Ireland |
|
2:00 to 2:30 PM |
PRP for OA Knee: Bench to bedside |
Sandeep Patel The Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh, India |
|
2:30 to 3:00 PM |
The Role of Extracellular Vesicles and Orthobiologics Secretome in Joint Preservation |
Elizabeth Vinod Centre for Stem Cell Research (a unit of inStem, Bengaluru) and CMC, Vellore, India |
|
3:00 to 3:30 PM |
Poster presentation and Industry Exhibition |
|
|
Session-2: MANUFACTURING AND REGULATORY ASPECTS IN CELL AND GENE THERAPY Chair: Cartikeya Reddy |
||
|
India Time |
Title |
Speaker Name |
|
3:30 to 4:00 PM |
Regulatory Paradigm of CAR-T therapies in India and Challenges and Promise of CAR-based therapies in India |
Akhil Kumar Aurigene Oncology Limited, Bangalore, India and Priyadarshini Chatterjee Aurigene Oncology Limited, Bangalore, India |
|
4:00 to 4:30 PM |
From Innovation to Translation to Patients: The Future of Genetically Engineered T-Cells for Human Therapeutics |
Bruce L. Levine The University of Pennsylvania, Philadelphia, US |
|
4:30 to 5:00 PM |
Mesenchymal stromal cells for clinical applications: CMC Challenges and Paths Forward |
Sowmya Viswanathan Schroeder Arthritis Institute, University Health Network and the University of Toronto, Ontario, Canada |
|
5:00 to 5:15 PM |
Break |
|
|
Session-3: TECHNOLOGY ADVANCES Chair: Soniya Nityanand |
||
|
India Time |
Title |
Speaker Name |
|
5:15 to 5:45 PM |
Development of targeted viral platform for selective gene transfer to human HSCs in vivo |
Dmitry M. Shayakhmetov Emory University School of Medicine Atlanta, USA |
|
5:45 to 6:15 PM |
Genetic and Transcriptional Engineering of Primary Human Blood Cells |
Rasmus O. Bak Aarhus University, Department of Biomedicine, Aarhus, Denmark |
|
6:15 to 6:45 PM |
Innovative Non-Genotoxic Cell and Gene Therapies for Fanconi Anemia |
Agnieszka Czechowicz Stanford University School of Medicine, Dept of Pediatrics Div. of Stem Cell Transplantation and Regenerative Medicine, Stanford, US |
|
KEYNOTE ADDRESS |
||
|
India Time |
Title |
Speaker Name |
|
6:45 to 7:45 PM |
The Concept of Innovation and Orchestration: Translating Engineered Cellular Therapies from Bench to Bedside |
Khalid Shah Center for Stem Cell and Translational Immunotherapy, Brigham and Women’s Hospital and Harvard Stem Cell Institute, Cambridge, USA |
|
End of Day-1 |
||
DAY-2: Friday, 2nd August, 2024
|
Session-4: INDUSTRY UPDATES |
||
|
India Time |
Title |
Speaker Name |
|
12:00 to 12:20 PM |
Non-Viral Chimeric Antigen Receptor (CAR) T Cells going Viral: Process Studies from Stanford Center for Cancer Cell |
Vimal Keerthi Stanford University School of Medicine, California, US |
|
12: 20 to 12:40 PM |
Writing the Future of Biologics with an Integrated Offering of Immunization, Libraries, and Machine Learning |
Jay Yang Twist Bioscience, San Francisco, California, US |
|
12:40 to 1:00 PM |
Transforming Viral Vector Production: Enhancing Efficiency and Scale-Up with OmniBRx’s Dynamic Bed Reactor Technology |
Ravindra Patel OmniBRx Biotechnologies Pvt Ltd. Ahmedabad, Gujarat, India |
|
1:00 to 2:00 PM |
Lunch Break |
|
|
Session-5: APPLICATION OF IPSC TECHHNOLOGY Chair: Maneesha S. Inamdar Co-Chair: Dhandapani Perundurai |
||
|
India Time |
Title |
Speaker Name |
|
2:00 to 2:30 PM |
Challenges for the development of pluripotent stem cell-based therapies and the role of international standards. |
Glyn Stacey International Stem Cell Banking Initiative, Barley, UK |
|
2:30 to 3:00 PM |
Developing iPSC-derived RPE cell replacement therapy for the treatment of AMD |
Rajarshi Pal Eyestem Research, Centre for Cellular and Molecular Platforms (C-CAMP), Bangalore, India |
|
3:00 to 3:30 PM |
Developing iPSC technologies to impact current challenges in the production of cell therapies |
Julia Neubauer Fraunhofer Institute for Biomedical Engineering IBMT, Germany |
|
3:30 to 3:45 PM |
Break |
|
|
Session-6: GENE THERAPY |
||
|
India Time |
Title |
Speaker Name |
|
3:45 to 4.15 PM |
New insights into the use of gamma delta T cells to treat childhood cancers |
H. Trent Spencer Emory University School of Medicine, Atlanta, USA |
|
4:15 to 4:45 PM |
Development of genome-modified generation ZZ (GenZZ) single-stranded AAV vectors with improved transgene expression |
Arun Srivastava University of Florida, Florida, USA |
|
4:45 to 5:15 PM |
Preclinical development of gene therapy for Diamond-Blackfan anemia |
Senthil Bhoopalan St. Jude Children’s Research Hospital, Memphis, USA |
|
5:15 to 6:00 PM |
Poster presentation and Industry Exhibition |
|
|
Session-7: Challenges And Opportunities in Gene Therapy |
||
|
India Time |
Title |
Speaker Name |
|
6:00 to 6:30 PM |
Development of pathophysiologicallyrelevant models of β-hemoglobinopahtues for therapeutic studies |
Sivaprakash Ramalingam CSIR–Institute of Genomics and Integrative Biology (CSIR–IGIB), New Delhi, India |
|
6:30 to 7:00 PM |
CAR T-cell induced T-cell malignancies |
Nirali Shah Center for Cancer Research, National Cancer Institute, Maryland, US |
|
7:00 to 7:30 PM |
Genome Editing of HSCs to Develop Stem Cell Based Therapies |
Matthew Porteus Stanford School of Medicine, California, USA |
|
KEYNOTE ADDRESS |
||
|
India Time |
Title |
Speaker Name |
|
7:30 to 8:30 PM |
Gene therapy for Haemophilia in India – The beginning of a New Era |
Alok Srivastava Centre for Stem Cell Research (A unit of inStem, Bengaluru) and Christian Medical College, Vellore, India |
|
End of Day-2 |
||
DAY-3: 3rd August 2024
|
Session-8: INDUSTRY UPDATES Chair: Arvind Ramanathan |
||
|
India Time |
Title |
Speaker Name |
|
12:20 to 12:40 PM |
Autologous CAR-T Cell Therapy Manufacturing Solution |
Pankaj Salvi Cytiva, Marlborough, US |
|
12:40 to 01:00 PM |
Thermo Fisher Scientific: Cell & Gene Therapy capabilities overview |
Uchenna Waturuocha Thermo Fisher Scientific, Mumbai, India |
|
01:00 to 02:00 PM |
Lunch Break |
|
|
Session-9: NON-VIRAL VECTOR BASED GENE THERAPY |
||
|
India Time |
Title |
Speaker Name |
|
2:00 to 2:30 PM |
Enhancing Natural killer cells proliferation and cytotoxicity using Imidazole-based lipid nanoparticles encapsulating interleukin-2 mRNA |
Chantal Pichon INSERM and University of Orléans, Orléans, France: Institut Universitaire de France, Paris |
|
2:30 to 3:00 PM |
MSC Extracellular Vesicles: Navigating Regenerative Medicine’s Therapeutic Landscape |
Sujata Mohanty All India Institute of Medical Sciences |
|
3:00 to 3:30 PM |
Long-lasting mRNA enabled protein replacement therapy with liver-specific lipid nanoparticle system: Haemophilia B as a model disease |
Srujan Marepally Centre for Stem Cell Research (a unit of inStem, Bengaluru), Vellore, India |
|
3:30 to 3:45 PM |
Break |
|
|
3:45 to 4:30 PM |
Poster presentation and Industry Exhibition |
|
|
Session-10: GENE EDITING Chair: Sanjeev Galande |
||
|
India Time |
Title |
Speaker Name |
|
4:30 to 5:00 PM |
Genome editing strategies for treating sickle cell disease |
Thiyagaraj Mayuranathan Centre for Stem Cell Research (a unit of inStem, Bengaluru), Vellore, India |
|
5:00 to 5:30 PM |
Epitope Editing for an Immunotherapy “Stealth” Hematopoiesis |
Pietro Genovese Harvard Medical School, Boston, USA |
|
5:30 to 6:00 PM |
Next-generation gene editing of human hematopoietic stem cells: from research to clinical translation |
Samuele Ferrari San Raffaele Telethon Institute for Gene Therapy (SR-Tiget), Milan, Italy |
|
Session-11: IMMUNE CELL THERAPY Chair: Amit Awasthi |
||
|
India Time |
Title |
Speaker Name |
|
6:00 to 6:30 PM |
CART Therapy in Pediatric Acute Lymphoblastic Leukemia |
Sunil Bhat Mazumdar Shaw Medical Centre, Narayana Health City, Bangalore, India |
|
6:30 to 7:00 PM |
Development of CAR-T cell products with non-viral vector system |
Yoshiyuki Takahashi Nagoya University Graduate School of Medicine, Nagoya, Japan |
|
7:00 to 7:30 PM |
Genetic manipulation of NK cells for enhanced immunotherapy |
Rizwan Romee Harvard Medical School, Dana Farber Cancer Institute, Boston, USA |
|
CONCLUDING REMARK |
||
|
End of Day-3 |
||